Marco Schito
Marco Schito
Scientific Director
Verified email at - Homepage
Cited by
Cited by
Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism
M Hesse, M Modolell, AC La Flamme, M Schito, JM Fuentes, AW Cheever, ...
The Journal of Immunology 167 (11), 6533-6544, 2001
CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal
O Schulz, AD Edwards, M Schito, J Aliberti, S Manickasingham, A Sher, ...
Immunity 13 (4), 453-462, 2000
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
SD Lawn, P Mwaba, M Bates, A Piatek, H Alexander, BJ Marais, ...
The Lancet infectious diseases 13 (4), 349-361, 2013
CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells
J Aliberti, C Reis e Sousa, M Schito, S Hieny, T Wells, GB Huffnagle, ...
Nature immunology 1 (1), 83-87, 2000
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ...
The Lancet infectious diseases 14 (4), 327-340, 2014
Drug-resistant tuberculosis: time for visionary political leadership
I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ...
The Lancet infectious diseases 13 (6), 529-539, 2013
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts
BJ Marais, K Lönnroth, SD Lawn, GB Migliori, P Mwaba, P Glaziou, ...
The Lancet infectious diseases 13 (5), 436-448, 2013
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
P Miotto, B Tessema, E Tagliani, L Chindelevitch, AM Starks, C Emerson, ...
European Respiratory Journal 50 (6), 2017
Tuberculosis biomarkers discovery: developments, needs, and challenges
RS Wallis, P Kim, S Cole, D Hanna, BB Andrade, M Maeurer, M Schito, ...
The Lancet infectious diseases 13 (4), 362-372, 2013
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
RS Wallis, M Maeurer, P Mwaba, J Chakaya, R Rustomjee, GB Migliori, ...
The Lancet infectious diseases 16 (4), e34-e46, 2016
Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing
CRyPTIC Consortium and the 100,000 Genomes Project
New England Journal of Medicine 379 (15), 1403-1415, 2018
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities
R McNerney, M Maeurer, I Abubakar, B Marais, TD Mchugh, N Ford, ...
Journal of Infectious Diseases 205 (suppl_2), S147-S158, 2012
Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review
SHE Kaufmann, C Lange, M Rao, KN Balaji, M Lotze, M Schito, AI Zumla, ...
The lancet Respiratory medicine 2 (4), 301-320, 2014
Clinical case definitions for classification of intrathoracic tuberculosis in children: an update
SM Graham, LE Cuevas, P Jean-Philippe, R Browning, M Casenghi, ...
Clinical Infectious Diseases 61 (suppl_3), S179-S187, 2015
Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues
CJ Meehan, GA Goig, TA Kohl, L Verboven, A Dippenaar, M Ezewudo, ...
Nature Reviews Microbiology 17 (9), 533-545, 2019
Drug-resistant tuberculosis—current dilemmas, unanswered questions, challenges, and priority needs
A Zumla, I Abubakar, M Raviglione, M Hoelscher, L Ditiu, TD Mchugh, ...
Journal of Infectious Diseases 205 (suppl_2), S228-S240, 2012
Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects
M Pai, M Schito
The Journal of infectious diseases 211 (suppl_2), S21-S28, 2015
Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology
CR e Sousa, G Yap, O Schulz, N Rogers, M Schito, J Aliberti, S Hieny, ...
Immunity 11 (5), 637-647, 1999
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project
M Zignol, AS Dean, N Alikhanova, S Andres, AM Cabibbe, DM Cirillo, ...
The Lancet infectious diseases 16 (10), 1185-1192, 2016
Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: implications of …
O Equils, ML Schito, H Karahashi, Z Madak, A Yarali, KS Michelsen, ...
The Journal of Immunology 170 (10), 5159-5164, 2003
The system can't perform the operation now. Try again later.
Articles 1–20